Comparison of the efficacy and safety of HLX-02 plus pertuzumab versus HLX-02 plus pyrotinib in neoadjuvant therapy for HER2-positive breast cancer

作者
Weifang Tang,Qi‐Lin Zhou,Jianjun Liu,Shikai Hong
出处
期刊:Therapeutic Advances in Medical Oncology [SAGE Publishing]
卷期号:18: 17588359261470682-17588359261470682
标识
DOI:10.1177/17588359261470682
摘要

Background: Whether the HLX-02 plus pertuzumab offers superior efficacy compared to the HLX-02 plus pyrotinib in the early-stage setting remains unclear, highlighting a critical gap in evidence for optimizing neoadjuvant therapy selection. Objective: To compare the efficacy and safety of neoadjuvant chemotherapy regimens combining the trastuzumab biosimilar HLX-02 with either pertuzumab or pyrotinib in patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Design: This is a retrospective cohort study. Methods: This retrospective cohort study enrolled patients with HER2-positive breast cancer who received neoadjuvant therapy at The First Affiliated Hospital of University of Science and Technology of China between October 2021 and July 2024. Participants were divided into two treatment groups: those receiving docetaxel, carboplatin, HLX‑02 plus pertuzumab (TCbHP group), and those receiving docetaxel, carboplatin, HLX‑02 (a trastuzumab biosimilar ) plus pyrotinib (TCbHPy group). To minimize selection bias, propensity score matching (PSM) was applied in a 1:2 ratio before evaluating efficacy and safety. The primary endpoint was the pathological complete response (pCR) rate. Secondary endpoints included safety outcomes, assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Results: A total of 101 patients were initially included. After PSM, 55 patients were selected (TCbHP group: n = 36; TCbHPy group: n = 19). The overall pCR rates were comparable between the groups (TCbHP group: 58.3% vs TCbHPy group: 52.6%, p = 0.778). Subgroup analysis showed that amonghormone receptor–positive (HR+) patients, pCR rates were 50.0% in the TCbHP group and 44.4% in the TCbHPy group. For HR negative (HR−) patients, pCR rates were 63.6% and 60.0%, respectively. The overall incidence of adverse events was 80.6% in the TCbHP group and 94.7% in the TCbHPy group. Notably, non-hematologic toxicities differed significantly between the groups, with a markedly higher incidence of diarrhea (grade ⩾3+: 47.3%) observed in the TCbHPy group. Conclusion: Both HLX‑02‑based neoadjuvant regimens exhibited comparable efficacy in achieving pCR in patients with HER2‑positive breast cancer. These findings indicate that HLX‑02, whether combined with pertuzumab or pyrotinib, represents a viable neoadjuvant strategy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无极微光的应助被团子采纳,获得20
刚刚
友好的璎完成签到,获得积分10
刚刚
小陈小陈科研有成完成签到,获得积分10
1秒前
1秒前
青光完成签到,获得积分10
1秒前
tt完成签到,获得积分10
1秒前
slk完成签到,获得积分10
1秒前
1秒前
勤劳寒烟完成签到,获得积分10
2秒前
辣味巧克力豆完成签到 ,获得积分10
2秒前
缓慢怀莲发布了新的文献求助10
2秒前
科研通AI2S的应助被niii采纳,获得10
2秒前
2秒前
漫漫完成签到,获得积分10
2秒前
关关完成签到,获得积分10
2秒前
小冯完成签到 ,获得积分10
2秒前
3秒前
2499297293发布了新的文献求助10
4秒前
fxx完成签到,获得积分10
4秒前
Liu发布了新的文献求助10
4秒前
one完成签到 ,获得积分10
4秒前
欢喜的亦竹完成签到,获得积分10
5秒前
慕青的应助被xiaodusb采纳,获得10
5秒前
英姑的应助被安静的匪采纳,获得10
5秒前
渣渣XM发布了新的文献求助10
5秒前
LDX完成签到 ,获得积分10
5秒前
哈哈哈完成签到,获得积分10
5秒前
6秒前
6秒前
卫星1019完成签到,获得积分10
6秒前
杜科研完成签到,获得积分10
6秒前
core完成签到,获得积分10
7秒前
长江水哗啦啦流完成签到,获得积分10
7秒前
红红完成签到,获得积分10
7秒前
共享精神的应助被忧伤的静竹采纳,获得10
7秒前
7秒前
8秒前
8秒前
所所的应助被迷人的周老师采纳,获得10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315